Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a

Neeraj Kumar, Moses Rodriguez

Research output: Contribution to journalArticle

24 Citations (Scopus)

Abstract

Background: Animal studies have shown that some human monoclonal antibodies promote myelin repair in models of demyelinating disease. Scleromyxedema is a dermatologic disorder associated with a monoclonal gammopathy and neurologic manifestations. The reason for occurrence of cutaneous reactions in interferon treated patients is unknown. Case description: A 37-year-old woman was started on weekly interferon beta-1a (IFN beta-1a) following a diagnosis of multiple sclerosis (MS). After having been on interferon therapy for three years, she developed skin lesions secondary to scleromyxedema. Her IFN beta-1a was discontinued and intravenous immunoglobulin therapy was started for her scleromyxedema. At a six-month follow up, her skin lesions improved and there was no recurrence of neurologic symptoms. Conclusions: This is the first report of occurrence of scleromyxedema in a patient with MS. While this could be a chance association, it does raise the question if her neurologic manifestations could be secondary to scleromyxedema. Further research into the mechanism of IFN related cutaneous side effects is needed. Evidence regarding the remyelinating nature of human monoclonal antibodies raises interest in the potential therapeutic role these antibodies may have.

Original languageEnglish (US)
Pages (from-to)85-86
Number of pages2
JournalMultiple Sclerosis
Volume10
Issue number1
DOIs
StatePublished - Feb 2004

Fingerprint

Scleromyxedema
Paraproteinemias
Multiple Sclerosis
Neurologic Manifestations
Skin
Interferons
Monoclonal Antibodies
Passive Immunization
Intravenous Immunoglobulins
Demyelinating Diseases
Myelin Sheath
Interferon beta-1a
Recurrence
Antibodies
Therapeutics
Research

Keywords

  • Interferons
  • Monoclonal antibodies
  • Multiple sclerosis
  • Scleromyxedema

ASJC Scopus subject areas

  • Clinical Neurology

Cite this

Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. / Kumar, Neeraj; Rodriguez, Moses.

In: Multiple Sclerosis, Vol. 10, No. 1, 02.2004, p. 85-86.

Research output: Contribution to journalArticle

@article{28b8eaca494847dbbc8bc540c6bd85f3,
title = "Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a",
abstract = "Background: Animal studies have shown that some human monoclonal antibodies promote myelin repair in models of demyelinating disease. Scleromyxedema is a dermatologic disorder associated with a monoclonal gammopathy and neurologic manifestations. The reason for occurrence of cutaneous reactions in interferon treated patients is unknown. Case description: A 37-year-old woman was started on weekly interferon beta-1a (IFN beta-1a) following a diagnosis of multiple sclerosis (MS). After having been on interferon therapy for three years, she developed skin lesions secondary to scleromyxedema. Her IFN beta-1a was discontinued and intravenous immunoglobulin therapy was started for her scleromyxedema. At a six-month follow up, her skin lesions improved and there was no recurrence of neurologic symptoms. Conclusions: This is the first report of occurrence of scleromyxedema in a patient with MS. While this could be a chance association, it does raise the question if her neurologic manifestations could be secondary to scleromyxedema. Further research into the mechanism of IFN related cutaneous side effects is needed. Evidence regarding the remyelinating nature of human monoclonal antibodies raises interest in the potential therapeutic role these antibodies may have.",
keywords = "Interferons, Monoclonal antibodies, Multiple sclerosis, Scleromyxedema",
author = "Neeraj Kumar and Moses Rodriguez",
year = "2004",
month = "2",
doi = "10.1191/1352458504ms987cr",
language = "English (US)",
volume = "10",
pages = "85--86",
journal = "Multiple Sclerosis",
issn = "1352-4585",
publisher = "SAGE Publications Ltd",
number = "1",

}

TY - JOUR

T1 - Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a

AU - Kumar, Neeraj

AU - Rodriguez, Moses

PY - 2004/2

Y1 - 2004/2

N2 - Background: Animal studies have shown that some human monoclonal antibodies promote myelin repair in models of demyelinating disease. Scleromyxedema is a dermatologic disorder associated with a monoclonal gammopathy and neurologic manifestations. The reason for occurrence of cutaneous reactions in interferon treated patients is unknown. Case description: A 37-year-old woman was started on weekly interferon beta-1a (IFN beta-1a) following a diagnosis of multiple sclerosis (MS). After having been on interferon therapy for three years, she developed skin lesions secondary to scleromyxedema. Her IFN beta-1a was discontinued and intravenous immunoglobulin therapy was started for her scleromyxedema. At a six-month follow up, her skin lesions improved and there was no recurrence of neurologic symptoms. Conclusions: This is the first report of occurrence of scleromyxedema in a patient with MS. While this could be a chance association, it does raise the question if her neurologic manifestations could be secondary to scleromyxedema. Further research into the mechanism of IFN related cutaneous side effects is needed. Evidence regarding the remyelinating nature of human monoclonal antibodies raises interest in the potential therapeutic role these antibodies may have.

AB - Background: Animal studies have shown that some human monoclonal antibodies promote myelin repair in models of demyelinating disease. Scleromyxedema is a dermatologic disorder associated with a monoclonal gammopathy and neurologic manifestations. The reason for occurrence of cutaneous reactions in interferon treated patients is unknown. Case description: A 37-year-old woman was started on weekly interferon beta-1a (IFN beta-1a) following a diagnosis of multiple sclerosis (MS). After having been on interferon therapy for three years, she developed skin lesions secondary to scleromyxedema. Her IFN beta-1a was discontinued and intravenous immunoglobulin therapy was started for her scleromyxedema. At a six-month follow up, her skin lesions improved and there was no recurrence of neurologic symptoms. Conclusions: This is the first report of occurrence of scleromyxedema in a patient with MS. While this could be a chance association, it does raise the question if her neurologic manifestations could be secondary to scleromyxedema. Further research into the mechanism of IFN related cutaneous side effects is needed. Evidence regarding the remyelinating nature of human monoclonal antibodies raises interest in the potential therapeutic role these antibodies may have.

KW - Interferons

KW - Monoclonal antibodies

KW - Multiple sclerosis

KW - Scleromyxedema

UR - http://www.scopus.com/inward/record.url?scp=0346076580&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346076580&partnerID=8YFLogxK

U2 - 10.1191/1352458504ms987cr

DO - 10.1191/1352458504ms987cr

M3 - Article

VL - 10

SP - 85

EP - 86

JO - Multiple Sclerosis

JF - Multiple Sclerosis

SN - 1352-4585

IS - 1

ER -